Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-01015-z
Abstract: Lorlatinib demonstrated efficacy (including intracranial activity) in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase I/II study (NCT01970865). This analysis describes the pharmacokinetics (PK) of lorlatinib following single and… read more here.
Keywords: phase; single multiple; alk positive; multiple dosing ... See more keywords